Back to Search
Start Over
FDA approves niraparib for HRD-positive advanced ovarian cancer
- Source :
- The Fly. October 23, 2019
- Publication Year :
- 2019
-
Abstract
- On October 23, the Food and Drug Administration approved niraparib, or ZEJULA, marketed by GlaxoSmithKline's (GSK) Tesaro, for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.603537070